The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Neuronal Synuclein Disease Endotypes 2024, 2025Testing Biofluid Samples from the Arizona Study of Aging and Neurodegenerative Disorders for Alpha-synuclein and Biomarkers of Alzheimer’s Disease
Study Rationale: The Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) has amassed a comprehensive collection of samples and longitudinal clinicopathological data. In this project, we...
-
Research Grant, 2025Evaluation of Novel PET Probes for Alpha-synuclein Imaging
Study Rationale: Aggregation of the protein alpha-synuclein into fibrils in Lewy bodies and Lewy neurites is the key pathological feature of Parkinson's disease (PD) and related synucleinopathies...
-
Research Grant, 2025Assessment of Artificial Intelligence (AI) and Blood-Brain Barrier Technology
Study Rationale: Companies are currently using artificial intelligence (AI) to design and develop new drugs and developing new ways to get drugs across the protective blood-brain barrier (BBB) and...
-
Biomarkers to Support Therapeutic Trials Program, 2025Ultra-sensitive Quantification of Phosphorylated LRRK2 in Biofluids from Clinical Trials of Therapeutic Candidates
Study Rationale: LRRK2 is a protein for which inappropriate activation is associated with Parkinson’s disease (PD). Investigators are therefore pursuing the activity of LRRK2 as a potential...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2025Elucidating the Role of PINK1 and PRKN in Cell Type-specific Responses to Alpha-synuclein Pathology
Study Rationale: Parkinson’s disease (PD) is associated with loss of dopamine neurons and aggregation of the protein alpha-synuclein. Mutations that impair the function of PINK1 and PRKN, proteins...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2025Accelerating Biological Understanding and Therapeutic Translation for PD-Biology
Study Rationale: Mutations in the PINK1 and Parkin genes cause early-onset Parkinson’s disease (PD). In rats with similar mutations in PINK1 and Parkin, we observed pronounced degeneration of nerve...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.